Olivia Vizier

Tessera Therapeutics, a well-funded startup based outside of Boston, announced Friday that it developed a lipid nanoparticle that shuttles a gene editing therapy directly to the bone marrow of mice.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.

Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired

Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are now rising challenges with the recruitment of patients in obesity trials.

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

So with positive data, and in the summer, we would begin another pivotal trial. This trial will be slightly different in that it will be slightly larger and will include both the US and European sites.

But behind the industry’s first uplisting of 2024, from San Diego biotech Skye Bioscience, is investors’ interest in an area of drug R&D that every therapeutics developer wants in on right now: the next wave of obesity medications.

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine,

Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.

Arrowhead Pharmaceuticals unveiled Phase IIb data for its investigational RNAi therapy plozasiran at ACC24, demonstrating steep triglyceride reductions at 24 weeks in patients with severely elevated triglyceride levels who are at risk of developing acute pancreatitis.

Aki Ko, chief executive officer at Elixirgen Therapeutics, sat down with NeurologyLive® at the conference to discuss the promise behind the therapy and why it can be successful in treating DMD.

Claris has found dHGF stable for three years at refrigeration temperatures and three months at room temperature

“Aligos is not only supportive of the progress this approval represents but happy to see this class validated as we begin the phase 2a trial of our own highly potent and selective THR-β agonist, ALG-055009.”

With global warming, fungi have become more adapted to higher temperatures like the human body, and with the use of fungicides in farming, fungi are more resistant to treatments.

“Eighty percent of our crop pathogens are fungi,” said Dr. John Rex, chief medical officer for biotech company F2G. “If we’re going to produce crops, especially in these changing environmental conditions, we’re going to need fungicides.”

In a report on the research, the company said that a single oral dose of MM120 met its key secondary endpoint, maintaining “clinically and statistically

AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumour microenvironment and led to epitope spreading against diverse tumour targets. Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer’s concentrated form of a blood clotting factor.

The trial included 25 people with pancreatic or colorectal cancer who had previously undergone surgery, seven of whom also had received radiation therapy. They were given up to 10 doses of the vaccine known as ELI-002, and the results were promising: 84 percent of all participants had positive T cell responses—and all of those who

Lumos Pharma is developing LUM-201 (ibutamoren) for the treatment of moderate pediatric growth hormone deficiency. PGHD is a rare disorder in which the body doesn’t make enough growth hormone.

Cerevance has shown that “we can tamp down the inflammation response, or the inflammasome, but keep all the other surveillance and other aspects of microglia still functioning as they should.” The company is now conducting a Phase I study of CVN293, with topline data expected in the second quarter of 2024.

Some venture firms are pumping money into publicly traded biotechnology companies, as falling share prices prompt these investors to expand their search for bargains to the public markets.

A vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, ELI-002, is showing promising early study results — but any potential broad commercial availability of the drug is likely several years away, as one researcher tells CURE®.

As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Lumos Pharma is dedicated to transforming the treatment landscape for rare pediatric diseases like PGHD. Lumos Pharma’s approach is not just about creating new drugs; it’s about rethinking the entire patient experience, prioritizing ease of use and minimizing the treatment burden on young patients and their families. Their work exemplifies a broader shift in the

Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple

Elicio Therapeutics on Thursday began treating patients with KRAS-mutant pancreatic ductal carcinoma in the Phase II portion of the AMPLIFY-7P trial in which it is testing the cancer vaccine ELI-002 7P as an adjuvant treatment.

With gonorrhea’s rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.